Table 2.

Breast cancer phenotype and clinical response to anthracycline-based chemotherapy

Entire populationBasal-like (n = 34)HER2* (n = 11)Luminal B (n = 26)Luminal A (n = 36)P
Clinical response to AC
    Complete response15 (14%)10 (29%)1 (10%)2 (8%)2 (6%)<0.0001
    Partial response50 (47%)19 (56%)6 (60%)13 (50%)12 (33%)
    Stable disease40 (38%)5 (15%)3 (30%)11 (42%)21 (58%)
    Progressive disease1 (1%)0001 (3%)
    Complete response + partial response65 (61%)29 (85%)7 (70%)15 (58%)14 (39%)<0.0001
Pathologic stage post-chemotherapy0.0004
    017 (16%)9 (27%)4 (36%)4 (15%)0
    I26 (25%)10 (31%)1 (9%)8 (31%)7 (21%)
    II33 (32%)8 (24%)5 (46%)8 (31%)12 (35%)
    III27 (26%)6 (18%)1 (9%)5 (19%)15 (44%)
    IV1 (1%)001 (4%)0
  • * One patient with the HER2+/ER− subtype was not evaluable for clinical response, and three patients did not undergo primary surgery.